Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™

Rhea-AI Summary

Catalyst Pharmaceuticals (Nasdaq: CPRX) announced on November 19, 2025 that it ranked #304 on the 2025 Deloitte Technology Fast 500™. The ranking is based on percentage revenue growth from fiscal year 2021 to 2024, during which Catalyst reported 249% revenue growth. The company attributes the growth to portfolio momentum and commercial execution and noted this is the second consecutive year it earned a Fast 500 placement, improving from #452 in 2024. The announcement frames the recognition as evidence of sustained commercial progress and operational discipline while reaffirming commitment to patients and long-term growth.

Positive

• Revenue +249% FY2021–FY2024
• Ranked #304 on 2025 Deloitte Technology Fast 500
• Improved from #452 in 2024 to #304 in 2025

Negative

• None.

Attributes 249% Revenue Growth to Portfolio Momentum and Focused Execution

CORAL GABLES, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced it ranked 304 on the 2025 Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 31st year. This achievement is based on percentage of revenue growth from fiscal year 2021 to 2024. Catalyst grew 249% during this period.

Catalyst’s President and Chief Executive Officer, Rich Daly, credits Catalyst’s best-in-class product portfolio and outstanding commercial capabilities for the Company’s 249% revenue growth. He said, “We’re proud to be recognized as one of the fastest-growing companies in North America for the second year in a row, a testament to the success of our commercial strategy, operational discipline, and talent across the organization. We remain committed to driving sustainable growth while continuing to prioritize the patients and communities we serve.”

“This year’s rankings highlight both enduring leadership and breakthrough momentum,” said Wolfe Tone, US Deloitte Private & Emerging Client Portfolio leader and partner, Deloitte Tax LLP. “More than half of the winners are prior honorees, yet the majority of the top ten are first-time entrants — demonstrating the staying power of established leaders alongside the accelerating growth of new innovators across key sectors. As in previous years, private companies continue to dominate, underscoring the agility that private enterprises bring to competitive markets, enabling the exceptional triple and quadruple digit growth reflected in these rankings.”

Catalyst previously ranked 452 as a Deloitte Technology Fast 500 award winner for 2024.

About the 2025 Deloitte Technology Fast 500

Now in its 31st year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2021 to 2024.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or proprietary technology that significantly contributes to the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US $5 million, with a growth rate of 50% or greater. Additionally, companies must be in business for a minimum of four years and be headquartered within North America (United States and Canada).

Please see www.deloitte.com/us/about for a detailed description of their legal structure.

About Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America's Fastest-Growing Companies.

For more information, please visit Catalyst's website at www.catalystpharma.com.

Investor Contact
Melissa Kendis, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
IR@catalystpharma.com

Media Contact
David Schull or Olipriya Das, Russo Partners
(858) 717-2310, 646 942 5588
david.schull@russopartnersllc.com, Olipriya.das@russopartnersllc.com

FAQ

What did Catalyst Pharmaceuticals (CPRX) announce on November 19, 2025?

Catalyst announced it ranked #304 on the 2025 Deloitte Technology Fast 500 and reported 249% revenue growth from 2021–2024.

How much did CPRX revenue grow between fiscal years 2021 and 2024?

Catalyst reported a 249% increase in revenue from fiscal year 2021 to 2024.

How did Catalyst's Deloitte Fast 500 ranking change from 2024 to 2025?

Catalyst improved its position from #452 in 2024 to #304 in 2025.

Why does the Deloitte Technology Fast 500 ranking matter for CPRX investors?

The ranking highlights percentage revenue growth over a multi‑year period, signaling momentum in commercial performance.

When was Catalyst's Fast 500 recognition publicly announced?

The company announced the recognition on November 19, 2025.

What drivers did Catalyst cite for its 249% revenue growth?

Catalyst attributed the growth to its product portfolio momentum and commercial capabilities.